Clinical Trial Search

Primary: Percentage of Participants With Sustained Virological Response at Week 48 — 52.7 Percentage of participants

Primary: 24 Hour Postoperative Opioid Consumption — 62.3; 45.6 mg — p=0.024

Primary: Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12 — -11.6; -62.6 percent change — p==0.039

Primary: Number of Participants With Grade ≥3 Toxicities Scored According to the CTCAE Version 4.0. — 0 participants

Primary: Percentage of Participants With Sustained Virologic Response at Week 72 — 33.5; 49.3 Percentage of participants — p=<0.0001

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 84.6; 96.0; 81.0; 76.0 percentage of participants

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 2; 4; 0; 5 participants

Primary: Percentage of Participants Who Achieved the Target Relative Dose Intensity (RDI) of 85% — 77.6; 90.0 Percentage of participants — p=0.1080

Primary: Percentage of Participants (Par) Withdrawn From the Study Due to "Poorly-controlled Asthma" During Period 2 — 4.9; 7.3; 8.1 Percentage of Participants

Primary: Incidence of Post Transplant Lymphoproliferative Disorder (PTLD) — 6 participants

Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157

Primary: Baseline-adjusted AUC0-24 for Plasma Total EPA + Total DHA — 17000; 18000; 12500 hr*nmol/mL — p=0.2702

Primary: Morphine Consumption — 29.2; 61.2 milligrams — p=<0.05

Primary: Safety: Percentage of Participants With Symptomatic Cardiac Events as Assessed by the Investigator — 0; 2.7; 1.3 percentage of participants

Primary: Number of Subjects Aged 18-49 Years Reporting Solicited Local Adverse Events (AEs). — 41; 32; 1; 0 Subjects